Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 686-690

  Santillan, Antonio ^a   Karam, Amer K ^b   Li, Andrew J ^b   Giuntoli II, Robert ^a   Gardner, Ginger J ^a   Cass, Ilana ^b   Karlan, Beth Y ^b   Bristow, Robert E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cytoreductive surgery; Ovarian cancer; Recurrence

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INGUINAL LYMPH NODE; KAPLAN MEIER METHOD; LENGTH OF STAY; LYMPH NODE METASTASIS; OPERATION DURATION; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REFERENCE DATABASE; REOPERATION; SURVIVAL TIME; TISSUE SECTION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; EPITHELIAL CELLS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 33846903602     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.020     Document Type: Article

References (21)

1. Berek J.S., Hacker N.F., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. 61 (1983) 189-193
2. Morris M., Gershenson D.M., and Wharton J.T. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol. Oncol. 33 (1989) 1-5
3. Janicke F., Holscher M., Kuhn W., von Hugo R., Pache L., and Siewert J.R. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70 (1992) 2129-2136
4. Segna R.A., Dottino P.r., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 57 (1993) 61-65
5. Eisenkop S.M., Friedman R.L., and Wang H. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer 76 (1995) 1606-1614
6. Vaccarello L., Rubin S.C., Vlamis V., et al. Cytoreductive surgery in ovarian carcinoma patients with documented previously complete surgical response. Gynecol. Oncol. 57 (1995) 61-65
7. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
8. Zang R.Y., Zhang Z.Y., Li Z.T., et al. Impact of secondary cytoreduction surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26 (2000) 798-804
9. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., and Genazzani A.R. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79 (2000) 344-349
10. Munkarah A., Levenback C., Wolk J.K., et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol. Oncol. 81 (2001) 237-241
11. Scarabelli C., Gallo A., and Garbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83 (2001) 504-512
12. Tay E., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99 (2002) 1008-1013
13. Uzan C., Morice P., Rey A., Pautier P., Camatte S., Lhomme C., et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann. Surg. Oncol. 11 (2004) 658
14. Meigs J.V. Tumors of the Female Pelvic Organs (1935), Macmillan, New York
15. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 42 (1975) 101-104
16. Bolis G., Scarfone G., and Giardina G. Carboplatin alone vs. carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol. Oncol. 81 (2001) 3-9
17. Parmar M.K., Ledermann J.A., and Colombo N. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
18. Pfisterer J., Plante M., and Vergote I. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a gynecologic cancer intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG, and the EORTC GCG. Proc. Am. Soc. Clin. Oncol. 23 (2004) 449
19. Cantu M.G., Buda A., Parma G., Rossi R., Floriani I., Bonazzi C., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol. 5 (2002) 1158-1160
20. Rubin S.C., Hoskins W.J., Hakes T.B., Reichman B.S., Chapman D., and Lewis Jr. J.L. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am. J. Obstet. Gynecol. 160 (1989) 667-671
21. Santillan A., Garg R., Zahurak M.L., Gardner G.J., Giuntoli II R.L., Armstrong D.K., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J. Clin. Oncol. 23 (2005) 9338-9343